Company: CMND
Filing Date: 2025-12-05
Form Type: F-1/A
Source: 0001213900-25-118772
Chunk: 294

Company: Clearmind Medicine Inc.
Filing Date: 2025-12-05
Form: F-1/A
Chunk 294
---
 (ii) an amount of cash equal to the fair market value of a common share. |

| b. | The following table summarizes the continuity of RSUs: |

|                            |     | Number of 
 RSUs      |          |   |     | Weighted    
 average     
 issue price 
 (C$)        |        |     | Weighted           
 average            
 issue price (USD$) |       |
|:---------------------------|:----|:----------|---------:|:--|:----|:------------|-------:|:----|:-------------------|------:|
| Balance, October 31, 2023  |     |           |    2,216 |   |     | $           | 138.55 |     | $                  | 96.06 |
| Granted                    |     |           |  591,460 |   |     |             |   1.86 |     |                    |  1.36 |
| Exercised                  |     |           | (329,338 | ) |     |             |   2.22 |     |                    |  1.65 |
| Balance, October 31, 2024  |     |           |  264,338 |   |     | $           |   2.55 |     | $                  |  1.80 |
| Granted (i)                |     |           |  627,777 |   |     |             |   1.55 |     |                    |  1.09 |
| Exercised                  |     |           | (803,867 | ) |     |             |   1.69 |     |                    |  1.20 |
| Balance, July 31, 2025 (*) |     |           |   88,248 |   |     | $           |   3.33 |     | $                  |  2.24 |

| (i) | During the nine months ended July 31, 2025, the Company issued 627,777 RSUs to consultants, directors and officers. The RSUs vested with a fair value of $686,986 (2024 - $629,720). |

| (*) | See note 14 regarding the exercise of RSUs. |

F-54 CLEARMIND MEDICINE INC. Notes to the Condensed Interim Consolidated Financial Statements For the three and nine months ended July 31,